US2014121358A1PendingUtilityA1
Humanized antibody and process for preparing same
Est. expiryMar 22, 2022(expired)· nominal 20-yr term from priority
Inventors:Hyo Jeong HongCheol Young MaengGi Hyeok YangMeong Hee JangMee Sook OhJin-Soo SongYoung Kug Jang
C07K 16/082C07K 16/461C07K 2317/92A61K 2039/505C07K 16/464C07K 2317/565C07K 16/18A61P 1/16
43
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
A humanized antibody is produced by process comprising the steps of: (a) selecting a specificity determining residue (SDR) of the complementarity determining region (CDR) of murine monoclonal antibody heavy chain and light chain variable regions; and (b) grafting said SDR to at least one of the corresponding amino acid sequences in human antibody variable regions.
Claims
exact text as granted — not AI-modified1 . (canceled)
2 . A process for preparing a humanized antibody consisting of the steps of:
(a) first performing alanine scanning mutagenesis for replacing each amino acid residue in the entire complementarily determining region (CDR) of a murine monoclonal antibody heavy chain and light chain variable regions with alanine to produce a series of transformants, selecting a transformant that has a lower affinity to the human antigen (KD) than of the original murine antibody, and determining the replaced amino acid residue of said selected transformant as a specificity determining residue (SDR); and (b) subsequently grafting all of the said SDR to the corresponding amino acid residues into human antibody variable regions.
3 . The process of claim 2 , wherein the CDR is selected from the group consisting of HCDR1(aa 31-35), HCDR2(aa 50-65) and HCDR3(aa 95-102) of the heavy chain (SEQ ID NO: 2); and LCDR1(aa 24-34), LCDR2(aa 50-56) and LCDR3(aa 89-97) of the light chain (SEQ ID NO: 4) of the murine monoclonal antibody variable regions of that bind hepatitis B virus pre-S 1 antigen, selecting a transformant that has an affinity to antigen which is more than 3 times lower than the original murine antibody when replaced with alanine, determining the replaced amino acid residue of said transformant as an SDR, and grafting said SDR to the corresponding amino acid sequence in human antibody heavy chain and light chain.
4 - 24 . (canceled)Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.